Indoco Remedies

Indoco Remedies

INDOCO.NSApproved
Mumbai, IndiaFounded 1947indoco.com

Indoco Remedies is a prominent Indian pharmaceutical player with over seven decades of history, specializing in the development, manufacturing, and marketing of a wide portfolio of generic and branded generic drugs. The company has established a robust presence in domestic and international markets through its vertically integrated operations spanning APIs, formulations, and ophthalmic products. Its strategic focus includes expanding its complex generics portfolio, strengthening its R&D pipeline, and leveraging its manufacturing capabilities for global partnerships and contract manufacturing opportunities.

Market Cap
$38.6M
Founded
1947
Employees
3000-4000
Focus
Biotech

INDOCO.NS · Stock Price

USD 47.874.70 (-8.94%)

Historical price data

AI Company Overview

Indoco Remedies is a prominent Indian pharmaceutical player with over seven decades of history, specializing in the development, manufacturing, and marketing of a wide portfolio of generic and branded generic drugs. The company has established a robust presence in domestic and international markets through its vertically integrated operations spanning APIs, formulations, and ophthalmic products. Its strategic focus includes expanding its complex generics portfolio, strengthening its R&D pipeline, and leveraging its manufacturing capabilities for global partnerships and contract manufacturing opportunities.

Technology Platform

Advanced manufacturing and process development for complex generic pharmaceuticals, with specialized expertise in sterile ophthalmic formulations, topical products, and API synthesis.

Funding History

1

Total raised: $15M

IPO$15MUndisclosedSep 30, 2004

FDA Approved Drugs

15
RIVAROXABANANDAAug 11, 2025
VARENICLINE TARTRATEANDAOct 29, 2024
CETIRIZINE HYDROCHLORIDEANDAOct 3, 2024

Opportunities

Significant growth opportunities exist in the US market through the launch of complex generic ophthalmic and topical products, which face less competition.
The expanding Indian pharmaceutical market and the global trend of outsourcing manufacturing (CDMO) to India present additional avenues for sustainable growth.

Risk Factors

Key risks include severe price erosion and intense competition in the US generics market, regulatory compliance risks at manufacturing plants, dependence on a few key products for US revenue, and vulnerability to currency fluctuations and supply chain disruptions for raw materials.

Competitive Landscape

Indoco faces intense competition from large Indian pharma companies (Sun Pharma, Cipla, Dr. Reddy's) domestically and global generic giants (Teva, Viatris) internationally. Its differentiation lies in specialized complex dosage forms like ophthalmics, vertical integration with API manufacturing, and a strong focus on quality and regulatory compliance.

Publications
13
Patents
5
FDA Approvals
15

Company Info

TypeTherapeutics
Founded1947
Employees3000-4000
LocationMumbai, India
StageApproved
RevenueRevenue Generating

Trading

TickerINDOCO.NS
ExchangeNSE

Contact

Therapeutic Areas

Anti-infectivesCardiovascularGastrointestinalOphthalmologyPain ManagementDermatology

Partners

Various global generic companies for contract manufacturing
SIMILAR COMPANIES
Mankind Pharma
Mankind Pharma
Pre-clinical · New Delhi
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Lupin Limited
Lupin Limited
Pre-clinical ·
Aurobindo Pharma
Aurobindo Pharma
Pre-clinical · Hyderabad
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile